IBEX 35
11.322,00 -16,20 (-0,14%) Euro Stoxx 50
4.983,67 +1,49 (+0,03%) Dólar/Euro
1,0852 +0,0016 (+0,15%) Petróleo Brent
81,58 -0,04 (-0,05%) Oro
2.347,70 +1,90 (+0,08%) Bitcoin EUR
62.486,77 +69,06 (+0,11%)
Acciones de biotecnología y medicamentos
7,47k seguidores • 31 símbolos Lista de control de Yahoo Finance
Sigue esta lista para descubrir las grandes empresas farmacéuticas y biotecnológicas.
Gestionada por Yahoo Finance
Sigue esta lista para descubrir las grandes empresas farmacéuticas y biotecnológicas. Estas empresas desarrollan medicamentos y tratamientos especializados para diversas enfermedades y afecciones. Aunque los medicamentos no siempre dan buenos resultados, los que tienen éxito suelen reportar ganancias cuantiosas durante un periodo, sobre todo si están patentados.
La lista incluye las acciones de 5 $ o más con un volumen de negociación diario que supera las 200 000 acciones, de media, en un periodo de tres meses. Esta lista se genera diariamente y se ordena por capitalización de mercado; las ganancias se basan en el precio de cierre más reciente y se limitan a las 30 acciones principales que cumplen los criterios.
Esta lista de control es similar a la que antes se denominaba "Lucha contra el cáncer".
Contexto
Yahoo Finanzas emplea algoritmos avanzados para monitorizar e identificar tendencias en los mercados financieros a nivel mundial. Te ofrecemos esta información en forma de listas de control.
Descubre otras ideas de inversiones ganadoras con el Inspector de Yahoo Finanzas.
¿Cómo se ponderan?Las acciones de esta lista de control están ponderadas de forma equitativa.
Rendimiento
| Lista de control | Cambio de hoy | Rendimiento 1 mes | Rendimiento 1 año | Rendimiento total |
|---|---|---|---|---|
| Acciones de biotecnología y medicamentos | +1.24% | - | - | - |
| ^GSPC | +0.80% | +2.92% | +23.48% | +5574.74% |
31 símbolos
| Símbolo | Nombre de la empresa | Último precio | Cambio | Cambio de % | Tiempo de mercado | Volumen | Vol medio (3 meses) | Capitalización de mercado |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 820.34 | +5.28 | +0.65% | 16:04 GMT-4 | 4,47M | 2,71M | 779,66B |
| NVO | Novo Nordisk A/S | 135.28 | +2.48 | +1.87% | 16:00 GMT-4 | 3,45M | 4,36M | 602,60B |
| JNJ | Johnson & Johnson | 146.67 | +1.39 | +0.96% | 16:00 GMT-4 | 14,62M | 7,70M | 352,99B |
| MRK | Merck & Co., Inc. | 125.54 | +1.01 | +0.81% | 16:00 GMT-4 | 18,15M | 8,57M | 317,97B |
| ABBV | AbbVie Inc. | 161.24 | +4.93 | +3.15% | 16:05 GMT-4 | 15,66M | 5,78M | 284,73B |
| AZN | AstraZeneca PLC | 78.02 | +1.25 | +1.63% | 16:00 GMT-4 | 4,78M | 5,23M | 241,90B |
| NVS | Novartis AG | 103.13 | +2.43 | +2.41% | 16:00 GMT-4 | 1,98M | 1,49M | 210,43B |
| RHHBY | Roche Holding AG | 32.01 | +0.44 | +1.39% | 16:00 GMT-4 | 1,96M | 2,97M | 206,41B |
| AMGN | Amgen Inc. | 305.85 | +4.85 | +1.61% | 16:00 GMT-4 | 4,49M | 2,67M | 164,07B |
| PFE | Pfizer Inc. | 28.66 | +0.46 | +1.63% | 16:00 GMT-4 | 78,29M | 42,12M | 162,40B |
| SNY | Sanofi | 49.03 | +1.20 | +2.51% | 16:00 GMT-4 | 2,10M | 1,98M | 122,55B |
| VRTX | Vertex Pharmaceuticals Incorporated | 455.34 | +12.29 | +2.77% | 16:00 GMT-4 | 2,36M | 1,06M | 117,50B |
| REGN | Regeneron Pharmaceuticals, Inc. | 980.16 | +10.25 | +1.06% | 16:00 GMT-4 | 833,17k | 440,60k | 108,00B |
| GSK | GSK plc | 44.77 | +0.75 | +1.70% | 16:00 GMT-4 | 3,62M | 3,12M | 91,29B |
| BMY | Bristol-Myers Squibb Company | 41.09 | +0.84 | +2.09% | 16:00 GMT-4 | 29,40M | 16,18M | 83,29B |
| GILD | Gilead Sciences, Inc. | 64.26 | +0.18 | +0.28% | 16:00 GMT-4 | 14,51M | 7,04M | 80,06B |
| ZTS | Zoetis Inc. | 169.56 | +0.12 | +0.07% | 16:00 GMT-4 | 4,09M | 3,65M | 77,37B |
| MRNA | Moderna, Inc. | 142.57 | -8.92 | -5.89% | 16:00 GMT-4 | 7,18M | 4,06M | 54,64B |
| TAK | Takeda Pharmaceutical Company Limited | 13.35 | +0.32 | +2.46% | 16:00 GMT-4 | 1,85M | 1,57M | 41,89B |
| HLN | Haleon plc | 8.44 | +0.06 | +0.72% | 16:00 GMT-4 | 3,58M | 6,91M | 38,54B |
| BIIB | Biogen Inc. | 224.94 | +4.87 | +2.21% | 16:00 GMT-4 | 1,87M | 1,22M | 32,75B |
| BAYRY | Bayer Aktiengesellschaft | 7.72 | +0.07 | +0.92% | 15:59 GMT-4 | 2,12M | 2,12M | 30,34B |
| BNTX | BioNTech SE | 100.6 | +1.85 | +1.87% | 16:00 GMT-4 | 1,62M | 723,66k | 24,24B |
| ARGX | argenx SE | 371.02 | +8.86 | +2.45% | 16:00 GMT-4 | 331,71k | 271,66k | 22,05B |
| TEVA | Teva Pharmaceutical Industries Limited | 16.93 | +0.03 | +0.18% | 16:00 GMT-4 | 12,78M | 9,86M | 19,18B |
| ALNY | Alnylam Pharmaceuticals, Inc. | 148.43 | -1.60 | -1.07% | 16:00 GMT-4 | 1,25M | 559,45k | 18,78B |
| GMAB | Genmab A/S | 28.205 | +0.22 | +0.77% | 16:00 GMT-4 | 479,40k | 482,25k | 18,19B |
| ALPMY | Astellas Pharma Inc. | 9.81 | +0.12 | +1.24% | 15:59 GMT-4 | 508,63k | 345,27k | 17,69B |
| RPRX | Royalty Pharma plc | 27.41 | +1.02 | +3.87% | 16:00 GMT-4 | 7,23M | 2,69M | 16,38B |
| BMRN | BioMarin Pharmaceutical Inc. | 75.07 | +0.59 | +0.79% | 16:00 GMT-4 | 2,55M | 1,70M | 14,25B |
Business WirePreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
COPENHAGEN, Denmark, June 02, 2024--Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of follicular lymphoma (FL). A preliminary analysis of data from the EPCORE™ NHL-2 study (NCT04663347), evaluating epcoritamab in combination with rituximab-lenalidomide (R2), demonstrated an overall response rate (ORR) of
Business WireTAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
WILMINGTON, Del., June 02, 2024--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CRT.
Business WireBelantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
PHILADELPHIA, June 02, 2024--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma
